

**Hepatitis Masterclass 2022** will be a hybrid event and it will be possible to follow it in person or via webinar. In both cases, tools will be used to ensure active participation.

Choose how to participate and register following the instructions in the boxes below.

### CME IN-PERSON ATTENDANCE

The course has been accredited by the Provider Prex (Rif. ECM: 75-352847-1) with educational objective n. 3 and it has been assigned 6 credits. The course is reserved to pharmacists and physicians specialised in: Internal Medicine, Infectious Diseases, General Practitioner, Gastroenterology, Haematology, Hospital Pharmacy. To obtain CME credits is necessary to attend the whole course, pass the evaluation test and the evaluation form online.

You may submit your registration on: [www.prex.it/eventi/masterclass-2022](http://www.prex.it/eventi/masterclass-2022)  
Registration is subject to availability.

### CME ONLINE ATTENDANCE

The course has been accredited by the Provider Prex (Rif. ECM: 75-352848-1) with educational objective n. 3 and it has been assigned 9 credits. The course is reserved to pharmacists and physicians specialized in: Internal Medicine, Infectious Diseases, General Practitioner, Gastroenterology, Haematology, Hospital Pharmacy. To obtain CME credits is necessary to attend the whole course, pass the evaluation test and take evaluation form online.

You may submit your registration on: [www.prex.it/eventi/masterclass-webinar-2022](http://www.prex.it/eventi/masterclass-webinar-2022)  
Registration is subject to availability.

With the unconditional support by



Provider ECM e Segreteria Scientifico-Organizzativa - Via A. Fava, 25 - 20125 Milano  
Tel. 02/67972201 - Fax 02/67972300 - E-mail: [segreteria@prex.it](mailto:segreteria@prex.it) - Website: [www.prex.it](http://www.prex.it)

MILANO


Le Village by CA

Corso di Porta Romana 61

# HEPATITIS MASTERCLASS

SCIENTIFIC COORDINATOR:  
Prof. Pietro Lampertico

16 SEPTEMBER 2022



In recent years, management of patients with liver-related diseases has been revolutionized by improvements in diagnostic techniques as well as by the availability of new therapeutic options.

The development of potent oral antivirals against hepatitis B (HBV) and C (HCV) viruses led to improvements in chronic viral hepatitis courses, which translated into reduced liver-related complications and improved patients' survival. The WHO goal of HBV and HCV elimination by 2030 represents the more ambitious large-scale clinical endpoint of the last years. For the first-time novel therapies against HDV have become available, opening the way to new medical challenges.

Nevertheless, liver-related complications still represent a major burden affecting outcomes and survival of patients with cirrhosis. Current efforts are focused toward development of personalized management approaches with optimization of diagnostic, therapeutic and surveillance algorithms. Non-invasive tools have gained a leading role in the identification of patients at increased risk of liver-related complications; but several efforts are deemed necessary in order to find therapeutic strategies able to impact on survival of patients with more advanced liver diseases.

Despite recent and profound changes in the epidemiology of liver diseases, Hepatologists are going to tackle new challenges, trying to achieve increasingly ambitious clinical goals.

## PROGRAMME

09:30 - 10:00	Welcome Breakfast
10:00 - 10:15	Meeting starts - <i>P. Lampertico</i>

### SESSION 1: CHRONIC VIRAL HEPATITIS - Moderators: *M. Buti* and *R. D'Ambrosio*

10:15 - 10:35	Strategies for universal HCV screening - <i>M. Buti</i>
10:35 - 10:50	Discussion
10:50 - 11:10	The Italian HCV screening program: lights and shadows - <i>R. D'Ambrosio</i>
11:10 - 11:30	Discussion
11:30 - 11:50	Current and future treatment approaches for HDV infection - <i>P. Lampertico</i>
11:50 - 12:10	Discussion
12:10 - 12:30	Diagnostic and therapeutic pathway 1 – Refined endoscopic surveillance in cirrhotics - <i>G. Tosetti</i>
12:30 - 12:50	Discussion
12:50 - 13:50	Light lunch

### SESSION 2: PORTAL HYPERTENSION - Moderators: *R. de Franchis* and *M. Primignani*

13:50 - 14:20	Redefining portal hypertension: from HVPG to liver stiffness - <i>R. de Franchis</i>
14:20 - 14:40	Discussion
14:40 - 15:00	Diagnostic and therapeutic pathway 2 – NSBB to prevent hepatic decompensation - <i>E. Degasperri</i>
15:00 - 15:20	Discussion
15:20 - 15:40	Infections in decompensated cirrhosis - <i>S.S. Piano</i>
15:40 - 16:00	Discussion
16:00 - 16:20	Coffee Break

### SESSION 3: HCC - Moderators: *D.J. Pinato* and *A. Sangiovanni*

16:20 - 16:40	Personalized surveillance strategies in HCV cured cirrhotics - <i>M.A. Iavarone</i>
16:40 - 17:00	Discussion
17:00 - 17:20	Diagnostic and therapeutic pathway 3 – Liver function to guide HCC treatment - <i>S. Bhoori</i>
17:20 - 17:40	Discussion
17:40 - 18:00	Immunotherapy to treat HCC - <i>D.J. Pinato</i>
18:00 - 18:20	Meeting closes - <i>P. Lampertico</i>

#### SCIENTIFIC COORDINATOR

Pietro Lampertico - Milano

#### SPEAKERS AND MODERATORS

Sherrie Bhoori - Milano  
 Maria Buti - Barcellona  
 Roberta D'Ambrosio - Milano  
 Roberto de Franchis - Milano

Elisabetta Degasperri - Milano  
 Massimo Alberto Iavarone - Milano  
 Salvatore Silvio Piano - Padova  
 David James Pinato - Londra

Massimo Primignani - Milano  
 Angelo Sangiovanni - Milano  
 Giulia Tosetti - Milano